GDRX earnings analysis
What we found in GDRX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
GoodRx's Q1 2026 financial results showed a decrease in revenue to $194.0 million, falling shy of the $184.1 million forecasted. The diluted EPS was reported at $0.00, below the expected $0.06, highlighting ongoing challenges amid a shifting pharmacy landscape. Despite this, the company raised its full-year 2026 revenue guidance to a range of $765 million to $785 million, indicating growth potential driven by strong performance in the Pharma Direct segment, which grew by 82% year-over-year.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Misses Estimates
- Q1 2026 revenue was $194.0 million, slightly below the estimated $184.1 million.
- EPS Below Expectations
- Reported EPS was $0.00, missing the expected $0.06.
- Strong Pharma Direct Growth
- Pharma Direct revenue surged 82% year-over-year to $52.2 million.
- Increased Cash from Operations
- Operating cash flow increased to $11.8 million from $9.4 million year-over-year.
- Raised Full-Year Revenue Guidance
- Full-year 2026 revenue guidance increased to $765-$785 million from $796.9 million last year.
- Stable Cash Position
- Cash and cash equivalents stood at $235.7 million as of March 31, 2026, with no material changes.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Declining Prescription Revenue
- Prescription transactions revenue fell 24%, from $148.9 million to $113.7 million year-over-year.
- Net Income Decrease
- Net income declined from $11.1 million (5.4% margin) in Q1 2025 to $1.2 million (0.6% margin) in Q1 2026.
- Increased Interest Expense
- Interest expenses remained significant at $9.8 million, with total other expenses of $8.37 million impacting profitability.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0
- Segment
- Prescription transactions
- Segment
- Subscription
- Segment
- Pharma Direct
- Segment
- Other
What they said about what is next.
Full-year 2026 revenue guidance raised from $796.9 million last year.
The filing reads about the same as the one before it.
What came before.
- 10-K · February 26, 2026
- GoodRx frames its strategy around expanding a consumer-focused digital healthcare platform that began with prescription price comparison and now targets multiple monetization points (prescription transactions,…
- 10-Q · August 6, 2025
- GoodRx reported quarterly revenue of $203,070,000 (up $2,460,000 vs. Q2 2024) and operating income rose to $26,809,000 (vs. $19,878,000 a year ago). Diluted EPS was $0.04 for the quarter and net income increased to…
- 10-Q · November 7, 2024
- GoodRx reported Q3 revenue of $195.251M, up from $179.958M a year earlier, and delivered an operating income of $20.407M versus an operating loss of $(38.330)M in the prior-year quarter. The company returned to net…
- 10-Q · May 9, 2024
- GoodRx Holdings, Inc. reported a strong performance for Q1 2024 with revenue of $197.88 million, a 7.5% increase from $183.99 million in Q1 2023. The company achieved a diluted EPS of $0.08, exceeding analysts'…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing GDRX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever